The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Results of a randomized phase II trial of an anti-notch 2/3, tarextumab (OMP-59R5, TRXT, anti-Notch2/3), in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC).
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Aduro Biotech; Astellas Pharma (I); Celgene; Celsion (I); Cipla; Exelixis (I); Gilead Sciences; Hexal (I); IntegraGen (I); Jennerex (I); Lilly (I); MedImmune; Merrimack; Novartis (I); Pharmacyclics; Sanofi; Silenseed; Vicus Therapeutics
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Immunomedics (Inst); Incyte (Inst); Momenta Pharmaceuticals (Inst); Myriad Genetics (Inst); OncoMed (Inst); Polaris (Inst); Sanofi (Inst)
 
Vaibhav Sahai
Honoraria - Celgene; Merrimack
Consulting or Advisory Role - Celgene
 
Johanna C. Bendell
Research Funding - Apexigen (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); SynDevRx (Inst); Taiho Pharmaceutical (Inst)
 
Andrea J. Bullock
Research Funding - OncoMed
 
Noelle K. LoConte
No Relationships to Disclose
 
Hassan Hatoum
No Relationships to Disclose
 
Paul S. Ritch
No Relationships to Disclose
 
Hugo Hool
No Relationships to Disclose
 
Joseph W. Leach
Consulting or Advisory Role - Biodesix
 
James Sanchez
No Relationships to Disclose
 
Davendra Sohal
Research Funding - Bayer (Inst); Celgene (Inst); Genentech (Inst); Novartis (Inst); OncoMed (Inst)
Travel, Accommodations, Expenses - Foundation Medicine
 
John H. Strickler
Consulting or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Celgene; Genentech/Roche; Onyx
Research Funding - Abbvie (Inst); Bayer (Inst); Exelixis (Inst); Gilead Sciences (Inst); MedImmune (Inst); OncoMed (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst)
 
Ravindranath Patel
No Relationships to Disclose
 
Andrea Wang-Gillam
Honoraria - Merrimack; Pfizer
Consulting or Advisory Role - Merrimack; pfizer
Research Funding - Aduro Biotech (Inst); AstraZeneca (Inst); CTI (Inst); EMD Serono (Inst); Halozyme (Inst); Merrimack (Inst); Newlink Genetics (Inst); OncoMed (Inst); pfizer (Inst); Precision Therapeutics (Inst); Prometheus (Inst)
Travel, Accommodations, Expenses - Axis Pharma
 
Irfan Firdaus
No Relationships to Disclose
 
Ann M. Kapoun
Employment - OncoMed
Leadership - OncoMed
Stock and Other Ownership Interests - OncoMed
Patents, Royalties, Other Intellectual Property - co-author of patents filed at OncoMed (Inst)
Travel, Accommodations, Expenses - OncoMed
 
Eric Holmgren
Employment - OncoMed
Stock and Other Ownership Interests - OncoMed
 
Lei Zhou
Stock and Other Ownership Interests - OncoMed
Consulting or Advisory Role - OncoMed
 
Jakob Dupont
Employment - OncoMed
Stock and Other Ownership Interests - OncoMed
 
Vincent J. Picozzi
Stock and Other Ownership Interests - Abbvie; Amgen; Johnson & Johnson
Honoraria - Celgene
Consulting or Advisory Role - Halozyme; Taiho Pharmaceutical
Research Funding - Aduro Biotech; Clovis Oncology; FibroGen; Immunomedics; Incyte; OncoMed; Theranostics Health